论文部分内容阅读
目的对比替吉奥胶囊联合奥沙利铂加与不加紫杉醇治疗晚期胃癌的临床疗效。方法选取2012年5月—2013年5月我院收治的晚期胃癌患者88例,将其随机分为对照组和观察组,各44例。对照组给予替吉奥胶囊+奥沙利铂化疗方案,观察组给予替吉奥胶囊+奥沙利铂+紫杉醇化疗方案,比较两组患者的临床疗效和毒副作用。结果两组总有效率比较,差异无统计学意义(P>0.05);观察组临床受益率为88.6%(39/44),高于对照组的70.5%(31/44)(P<0.05);观察组周围神经毒性发生率、脱发发生率低于对照组(P<0.01)。结论替吉奥胶囊联合奥沙利铂加紫杉醇较不加紫杉醇治疗晚期胃癌疗效好,且毒副作用发生率低,安全性较高。
Objective To compare the clinical curative effect of tigeo capsule with oxaliplatin plus paclitaxel in the treatment of advanced gastric cancer. Methods From May 2012 to May 2013, 88 patients with advanced gastric cancer admitted to our hospital were randomly divided into control group and observation group, 44 cases in each group. The control group was given Teglitazone + oxaliplatin chemotherapy. The observation group was given Teglitazone + oxaliplatin + paclitaxel chemotherapy, and the clinical efficacy and side effects of the two groups were compared. Results The total effective rate was no significant difference between the two groups (P> 0.05). The clinical benefit rate in the observation group was 88.6% (39/44), which was higher than that in the control group (70.5%, 31/44, P <0.05) The incidence of neurotoxicity and hair loss in the observation group were lower than those in the control group (P <0.01). Conclusion TEGO capsules combined with oxaliplatin plus paclitaxel have better efficacy than paclitaxel in the treatment of advanced gastric cancer with low incidence of toxic and side effects and high safety.